Multiple Oral Doses Of PH-797804 In Healthy Japanese Adult Subjects

Pfizer

Status and phase: Completed; Phase 1

Conditions: Healthy

Treatments: Drug: 10 mg; Drug: 5 mg; Drug: 1 mg

Study type: Interventional

Funder types: Industry

Identifiers

NCT01217918

A6631027

Details and patient eligibility

About

Study A6631027 will evaluate the safety, tolerability and pharmacokinetics of PH-797804 when administered to healthy Japanese subjects once a day (QD) for 10 days.

Enrollment: 30 patients

Sex: All

Ages: 18 to 55 years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

• Healthy Volunteers
• Japanese

Exclusion criteria

• Subjects with clinically significant skin lesions
• Subjects with known tuberculosis infection

Trial design

Primary purpose: Basic Science

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Double Blind

---

30 participants in 3 patient groups

Cohort 1

Experimental group

Description:

PH-797804

Treatment:

Drug: 1 mg

Cohort 2

Experimental group

Description:

PH-797804

Treatment:

Drug: 5 mg

Cohotr 3

Experimental group

Description:

PH-797804

Treatment:

Drug: 10 mg